Search results for "Asthma"

showing 10 items of 860 documents

Effects of Exercise on the Airways

2012

In the last ten years, the effects of exercise on bronchial epithelial cells and inflammatory cells in the airways have been studied in detail, and such new information has been combined with previous knowledge on bronchial reactivity and asthma evoked by exercise in asthmatic patients and athletes. The resulting picture is very complex, and the potential clinical consequences are often contradictory, suggesting the opportunity to define different phenotypes of exercise-associated airway changes (Lee & Anderson, 1985; Haahtela et al., 2008; Moreira et al., 2011a). Studies in asthmatic athletes in the 90’ had began to explore the possibility that airway inflammation might be involved in exer…

Section (typography)Library science030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato RespiratorioSettore BIO/09 - Fisiologia3. Good health03 medical and health sciencesMolecular Immunology0302 clinical medicineAirways Asthma Exercise030228 respiratory systemResearch councilPolitical scienceSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' Motorie
researchProduct

Vitamin D Insufficiency In Adult Asthma Is Associated With Asthma Severity And Control

2012

Data in asthmatic children suggest that low vitamin D levels are associated with poor asthma control, reduced lung function, and increased medication intake. To investigate the role of vitamin D insufficiency in adult asthmatics 25-hydroxyvitamin D was measured in 280 adult patients with asthma (mean±SEM: 45.0±0.8 yrs., 40% male, FEV1 74.9±1.4%) and correlated with clinical parameters of asthma control. The majority of patients had severe asthma (n=155, 55%) and were uncontrolled (n=144, 51%). Serum levels of vitamin D were significantly related to asthma severity (mean±SEM: intermittent 31.1±3.2 ng/ml, mild 27.3±1.6 ng/ml, moderate 26.5±1.5, severe 24.0±0.9, p=0.046) and asthma control (co…

Serum vitaminmedicine.medical_specialtybusiness.industryAsthma severitySPUTUM EOSINOPHILIAmedicine.diseaseGastroenterologyrespiratory tract diseasesUncontrolled asthmaInternal medicineImmunologyVitamin D and neurologyMedicineIn patientbusinessLung functionAsthmaD34. ASTHMA EPIDEMIOLOGY
researchProduct

Causes of Allergic Rhinitis and Asthma

2009

Settore MED/10 - Malattie Dell'Apparato RespiratorioAsthmaAllergic Rhiniti
researchProduct

Effects of rowing training on airway responsiveness in asthmatics

2012

We previously reported that after a short course of rowing training the responsiveness to methacholine (Mch) in the absence of deep inspiration (DI) decreased in healthy subjects. We assessed whether a similar beneficial effect of exercise on airway responsiveness could occur in asthmatics. Nine patients (M/F: 3/6; mean age±SD: 24±2 yrs) with mild untreated asthma (FEV(1): 100±7.4% pred, FEV(1)/VC 90±6.5%) underwent a series of single dose Mch bronchoprovocations in the absence of DI in the course of a indoor rowing training consisted of two to three sessions per week for 10 weeks (total 28 sessions). Each session included a warm-up period for 20 min (running and stretching), and a specific…

Settore MED/10 - Malattie Dell'Apparato Respiratorioairway responsiveness rowing asthmaSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieSettore BIO/09 - Fisiologia
researchProduct

Applicability of the asthma control test (ACT) in elderly asthmatics

2008

Settore MED/10 - Malattie Dell'Apparato Respiratorioasthma elderly
researchProduct

Asthma in the elderly

2009

Settore MED/10 - Malattie Dell'Apparato RespiratorioelderlyAsthma
researchProduct

Clinical evolution of asthma from early childhood to development age

2005

The aim of study was to conduct evaluation over twenty years on patients with relapsing wheezing breathing since their early years of life. The research included a period of observation started in 1978 up to 2002. The follow-up included 381 patients. The enrolment was carried out during the first 15 years, after being evaluated during outpatient or/ and hospitalization the children with a clinical picture resembling asthma (at least three episodes of dyspnea for a year, at least 2 years prior to our first observation). During follow-up the rhole of some risk factors in childhood able to affect the persistency of asthma in adulthood was considered. An early onset of symptoms resulted to be a…

Settore MED/31 - OtorinolaringoiatriaClinical evolution of asthmaSettore MED/32 - Audiologia
researchProduct

Beliefs and preferences regarding biological treatments for severe asthma

2020

Background: Severe asthma is a serious condition with a significant burden on patients' morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and interleukin-5 (IL5) mediated pathways are now available. Due to the lack of direct comparison studies, the choice of which medication to use varies. We aimed to explore the beliefs and practices in the use of biological therapies in severe asthma, hypothesizing that differences will occur depending on the prescribers’ specialty and experience. Methods: We conducted an online survey composed of 35 questions in English. The survey was circulated via the INterasma Scientific Network (INESNET) platform as well as throu…

Severe asthmaBehavior; Belief; Biological drug; Severe asthmainterleukine 5 IgEMULTICENTERDiseaseOmalizumabADD-ON THERAPYBehavior Belief Biological drug Severe asthmaDOUBLE-BLIND0302 clinical medicineMedicine and Health SciencesImmunology and AllergyEosinophil IL5 [Eos]030223 otorhinolaryngologyPulmonologistssevere asthma biological drug belief behavior3. Good healthBeliefSAFETYmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyEos: Eosinophil IL5ImmunologyBiological drugSpecialtylong-acting beta2-agonist OMASocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioArticle03 medical and health sciencesQuality of life (healthcare)Omalizumab. OMA/IL5 Omalizumab plus anti-IL5 moleculeOMALIZUMABmedicineIntensive care medicineAsthmaBehaviorINterasma Scientific Network LABAbusiness.industryMEPOLIZUMABmedicine.diseaseEFFICACYICS inhaled corticosteroidsLIFE030228 respiratory systemImmunoglobulin E INESNETAllergistslcsh:RC581-607businessMepolizumab
researchProduct

Characteristics and treatment regimens across ERS SHARP severe asthma registries

2020

Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many …

Severe asthmaPediatricsMESH: RegistriesMESH: AsthmaCross-sectional studyRespiratory SystemMedizin[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract0302 clinical medicineMESH: BelgiumBelgiumMedicine researchAnti-Asthmatic AgentsRegistries030212 general & internal medicine[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology10. No inequality11 Medical and Health SciencesNetherlands2. Zero hungereducation.field_of_studySHARP CRCMESH: Administration InhalationMESH: Anti-Asthmatic Agents3. Good healthEuropeItalyMESH: PolandMESH: Swedenmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyMESH: HungaryPopulationInvestigació mèdicaSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesMESH: Cross-Sectional StudiesAdministration InhalationMESH: SpainmedicineHumanseducationAsmaRetrospective StudiesAsthmaSwedenHungaryMESH: Humansbusiness.industrySettore MED/09 - MEDICINA INTERNAMESH: ItalyMESH: Retrospective StudiesRetrospective cohort studyOriginal Articlesasthmamedicine.diseaseAsthmaClinical trialCross-Sectional StudiesClinical research030228 respiratory systemSpainMESH: NetherlandsMESH: EuropePolandbusinessBody mass indexMepolizumabEuropean Respiratory Journal
researchProduct

Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study

2021

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) affects around 60% of patients with severe eosinophilic asthma (SEA). Benralizumab was recently approved for SEA add-on treatment. Objective: To assess the real-world effectiveness of benralizumab in SEA with or without CRSwNP. Methods: We conducted a multicenter observational study, including patients with SEA treated with benralizumab for 24 weeks in 12 Italian specialized facilities. Asthma exacerbations, Asthma Control Test (ACT), lung function, oral corticosteroid (OCS) dosage, and eosinophil and basophil count in peripheral blood were recorded at baseline and after 4, 12, and 24 weeks. The 22-item Sino-Nasal Outcome Test (S…

Severe asthmaVital capacitymedicine.medical_specialtymedicine.drug_classSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedFEV1/FVC ratiochemistry.chemical_compoundNasal PolypsInternal medicinemedicineHumansImmunology and AllergyNasal polypsAnti-Asthmatic AgentsIL-5Nasal polypbusiness.industryMinimal clinically important differenceBenralizumabFunctional endoscopic sinus surgeryrespiratory systemEosinophilBenralizumabmedicine.diseaseAsthmaChronic rhinosinusitismedicine.anatomical_structureReal-worldchemistryChronic rhinosinusitiCorticosteroidbusinessHumanThe Journal of Allergy and Clinical Immunology: In Practice
researchProduct